Ask AI
EMERALD-3
EMERALD-3: Phase III Trial of Tremelimumab + Durvalumab ± Lenvatinib Combined With TACE in Unresectable Embolization-Eligible HCC

Released: June 11, 2026

Activity

Progress
1
Course Completed
Activity Information

Released: June 11, 2026